Cargando…

Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells

The present study aimed to investigate the anticancer effect of sorafenib combined with silencing of activating transcription factor 2 (ATF2) in hepatocellular carcinoma (HCC) cells and to assess the underlying molecular mechanisms. Huh-7 HCC cell line was selected for the present study. Small inter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Lifang, Cai, Lijing, Luo, Laibang, Tang, Zhimou, Meng, Xiaohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983979/ https://www.ncbi.nlm.nih.gov/pubmed/29693700 http://dx.doi.org/10.3892/mmr.2018.8921

Ejemplares similares

Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
por: Yao, Leyi, et al.
Publicado: (2022)

Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3
por: Hu, Zongqiang, et al.
Publicado: (2023)

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
por: Zhu, Qiankun, et al.
Publicado: (2020)

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death
por: Ding, Bisha, et al.
Publicado: (2021)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
por: Li, Xuguang, et al.
Publicado: (2020)

CENPB promotes the proliferation of hepatocellular carcinoma and is directly regulated by miR-29a
por: Wang, Xuyang, et al.
Publicado: (2023)

PCNT is a prognostic biomarker correlated with tumor immune microenvironment in hepatocellular carcinoma and promotes tumor progression by inhibiting cell cycle arrest
por: Wang, Xuyang, et al.
Publicado: (2023)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]
Publicado: (2021)

MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma
por: Zhu, Jinrong, et al.
Publicado: (2022)

Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol–sorafenib hybrids
por: Awasthi, Bhuwan Prasad, et al.
Publicado: (2021)

HSP27 promotes epithelial-mesenchymal transition through activation of the β-catenin/MMP3 pathway in pancreatic ductal adenocarcinoma cells
por: Fang, Zehong, et al.
Publicado: (2019)

Fabrication and characterization of nanodelivery platform based on chitosan to improve the anticancer outcome of sorafenib in hepatocellular carcinoma
por: Albalawi, Fahad, et al.
Publicado: (2023)

ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma
por: Cai, Mengxing, et al.
Publicado: (2023)

Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib
por: Chen, Zhuo, et al.
Publicado: (2018)

Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells
por: Moon, Byul, et al.
Publicado: (2022)

TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression
por: Ho, Victor, et al.
Publicado: (2015)

LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells
por: Chen, Yan, et al.
Publicado: (2018)

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling
por: Zhou, Xin, et al.
Publicado: (2022)

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
por: Xia, Shunjie, et al.
Publicado: (2020)

Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma
por: Hashiba, Tomomi, et al.
Publicado: (2020)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma
por: Lu, Shuai, et al.
Publicado: (2018)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma
por: Guo, Yulin, et al.
Publicado: (2017)

Tumor-associated macrophages promote resistance of hepatocellular carcinoma cells against sorafenib by activating CXCR2 signaling
por: Wang, Hao-Chen, et al.
Publicado: (2022)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
por: Chen, Jiang, et al.
Publicado: (2016)

Identification and validation of potential key long noncoding RNAs in sorafenib-resistant hepatocellular carcinoma cells
por: Wu, Manya, et al.
Publicado: (2020)

Targeting Yes1 Associated Transcriptional Regulator Inhibits Hepatocellular Carcinoma Progression and Improves Sensitivity to Sorafenib: An in vitro and in vivo Study
por: Guo, Liwen, et al.
Publicado: (2020)

Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma
por: Zhang, Youfu, et al.
Publicado: (2022)

YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma
por: Kong, Jian, et al.
Publicado: (2014)

CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma
por: Li, Bowen, et al.
Publicado: (2021)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Ma, Yongfang, et al.
Publicado: (2021)

Global transcriptomic study of circRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells
por: Wu, Man-ya, et al.
Publicado: (2020)

Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma
por: Liang, Chao, et al.
Publicado: (2020)

Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids
por: Wang, Siqi, et al.
Publicado: (2020)

Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation
por: Jiang, Yuchuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h9uavu5o63gndavb6p8p385c3o